{"id":"https://openalex.org/W7129338317","doi":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28","title":"Abstract PS5-01-28: Us real-world clinical outcomes of tucatinib, trastuzumab, and capecitabine following trastuzumab deruxtecan for the treatment of her2+ metastatic breast cancer","display_name":"Abstract PS5-01-28: Us real-world clinical outcomes of tucatinib, trastuzumab, and capecitabine following trastuzumab deruxtecan for the treatment of her2+ metastatic breast cancer","publication_year":2026,"publication_date":"2026-02-17","ids":{"openalex":"https://openalex.org/W7129338317","doi":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28"},"language":"en","primary_location":{"id":"doi:10.1158/1557-3265.sabcs25-ps5-01-28","doi":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5126248718","display_name":"J. Chien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Chien","raw_affiliation_strings":["1Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056473602","display_name":"Edward E. Neuberger","orcid":"https://orcid.org/0000-0003-4037-0295","observed_orcids":["https://orcid.org/0000-0003-4037-0295"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Neuberger","raw_affiliation_strings":["2Pfizer Inc., Pfizer Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., Pfizer Inc., New York, NY","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126245766","display_name":"S. Simon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138890","display_name":"Pfizer (Spain)","ror":"https://ror.org/03x2xt559","country_code":"ES","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210138890"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"S. Simon","raw_affiliation_strings":["3Pfizer S.L.U., Pfizer S.L.U., Madrid, SPAIN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer S.L.U., Pfizer S.L.U., Madrid, SPAIN","institution_ids":["https://openalex.org/I4210138890"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126187210","display_name":"K. Watkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Watkins","raw_affiliation_strings":["2Pfizer Inc., Pfizer Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., Pfizer Inc., New York, NY","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072365414","display_name":"G. Curigliano","orcid":"https://orcid.org/0000-0003-1781-2518","observed_orcids":["https://orcid.org/0000-0003-1781-2518"]},"institutions":[{"id":"https://openalex.org/I189158943","display_name":"University of Milan","ror":"https://ror.org/00wjc7c48","country_code":"IT","type":"education","lineage":["https://openalex.org/I189158943"]},{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"G. Curigliano","raw_affiliation_strings":["4European Institute of Oncology, IRCCS, and Department of Oncology and Hemato-Oncology, University of Milano La Statale, Milano, ITALY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4European Institute of Oncology, IRCCS, and Department of Oncology and Hemato-Oncology, University of Milano La Statale, Milano, ITALY","institution_ids":["https://openalex.org/I189158943","https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064628466","display_name":"B. Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Li","raw_affiliation_strings":["2Pfizer Inc., Pfizer Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., Pfizer Inc., New York, NY","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126179342","display_name":"S. Stergiopoulos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Stergiopoulos","raw_affiliation_strings":["2Pfizer Inc., Pfizer Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., Pfizer Inc., New York, NY","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088231459","display_name":"Maciej Czachorowski","orcid":"https://orcid.org/0000-0002-1469-6120","observed_orcids":["https://orcid.org/0000-0002-1469-6120"]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Czachorowski","raw_affiliation_strings":["5Pfizer Ltd., Pfizer Ltd., Surrey, UNITED KINGDOM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Pfizer Ltd., Pfizer Ltd., Surrey, UNITED KINGDOM","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070505607","display_name":"Haruka Itakura","orcid":"https://orcid.org/0000-0003-4382-0183","observed_orcids":["https://orcid.org/0000-0003-4382-0183"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Itakura","raw_affiliation_strings":["6Medicine - Med/Oncology, Stanford University School of Medicine, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Medicine - Med/Oncology, Stanford University School of Medicine, Stanford, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"4_Supplement","first_page":"PS5","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-metastatic-breast-cancer","display_name":"HER2-positive metastatic breast cancer","score":0.9380000233650208},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9860000014305115},{"id":"https://openalex.org/keywords/tucatinib","display_name":"tucatinib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.6420000195503235},{"id":"https://openalex.org/keywords/time-to-next-treatment","display_name":"time to next treatment","score":0.8669999837875366},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.9110000133514404},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6100000143051147},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.8339999914169312},{"id":"https://openalex.org/keywords/fourth-line-treatment","display_name":"fourth-line treatment","score":0.9860000014305115},{"id":"https://openalex.org/keywords/hormone-receptor-status","display_name":"hormone receptor status","score":0.6119999885559082},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.31299999356269836},{"id":"https://openalex.org/keywords/natural-language-processing","display_name":"natural language processing","score":0.4090000092983246},{"id":"https://openalex.org/keywords/electronic-health-records","display_name":"electronic health records","score":0.8759999871253967},{"id":"https://openalex.org/keywords/flatiron-health","display_name":"Flatiron Health","score":0.781000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9294999837875366},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.9246000051498413},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8776000142097473},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.824999988079071},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7081999778747559},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6848000288009644},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5860000252723694},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5322999954223633},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.4596000015735626},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4544999897480011},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4390999972820282},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43810001015663147},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.36480000615119934},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3499999940395355},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.3395000100135803},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.3384999930858612},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3328000009059906},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.33009999990463257},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.2948000133037567},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.2824999988079071},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2809999883174896},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.2799000144004822},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.25929999351501465},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.2572000026702881}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1557-3265.sabcs25-ps5-01-28","doi":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps5-01-28","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/4","score":0.6029767990112305,"display_name":"Quality education"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"US":[2,141,183],"and":[3,14,34,57,92,112,150,189,200,232,274,284,296,307,336,387,430],"EU":[4],"treatment":[5,55,63,87,364,437],"guidelines":[6],"currently":[7],"recommend":[8],"tucatinib":[9],"in":[10,17,35,75,134,139,147,224,236,276,286,351,372,390,394],"combination":[11],"with":[12,22,41,66,136,145,165,197,206,213,222,319,356,365,384],"trastuzumab":[13,47,433],"capecitabine":[15,431],"(TTC)":[16],"third-line":[18],"(3L)":[19],"for":[20,38,64,304,435],"patients":[21,40,65,76,135,164,205,287,318],"human":[23],"epidermal":[24],"growth":[25],"factor":[26],"receptor":[27,298],"2-positive":[28],"(HER2+)":[29],"metastatic":[30,440],"breast":[31,207,441],"cancer":[32,442],"(MBC),":[33],"second-line":[36],"(2L)":[37],"those":[39],"brain":[42],"metastases":[43],"(BM).":[44],"More":[45],"recently,":[46],"deruxtecan":[48,434],"(T-DXd)":[49],"has":[50],"become":[51],"the":[52,140,172,243,380,436,447],"recommended":[53],"2L":[54],"option":[56],"may":[58],"be":[59,349],"considered":[60],"as":[61],"first-line":[62],"rapid":[67],"progression":[68],"after":[69,79,363],"(neo)adjuvant":[70],"therapy.":[71],"Previous":[72],"real-world":[73,132,392,424],"studies":[74],"receiving":[77,168],"TTC":[78,117,146,169,223,246,323,361],"T-DXd":[80,294],"have":[81],"reported":[82],"median":[83,93,328,337],"time":[84],"to":[85,123,130,218,249,399],"next":[86],"(TTNT)":[88],"of":[89,97,163,245,256,293,382,427,438,446],"6":[90],"months":[91,335,344],"overall":[94],"survival":[95],"(OS)":[96],"13":[98],"months;":[99],"however,":[100],"these":[101],"study":[102,128,258],"populations":[103],"included":[104,210],"later":[105],"line":[106],"treatment,":[107,295],"a":[108,159,373,395],"small":[109],"sample":[110],"size,":[111],"did":[113],"not":[114,234,270],"solely":[115],"include":[116],"immediately":[118,153,229,324,362],"following":[119,154,230,325,432],"T-DXd,":[120,231,366],"limiting":[121],"applicability":[122],"current":[124,400],"clinical":[125,237,401,425],"practice.":[126,402],"This":[127,182],"aimed":[129],"describe":[131],"outcomes":[133,266,308,347,426],"HER2+":[137,166,214,320,357],"MBC":[138,167,215,321,358],"who":[142],"were":[143,211,233,240,269,302,309],"treated":[144,221],"2L,":[148,225],"3L":[149,226],"fourth-line":[151],"(4L)":[152],"T-DXd.":[155,326],"Methods:":[156],"We":[157],"conducted":[158],"retrospective":[160],"cohort":[161],"analysis":[162],"therapy":[170],"using":[171,193,311],"Flatiron":[173],"Health":[174],"electronic":[175],"health":[176],"record":[177],"(EHR)-derived":[178],"deidentified":[179],"longitudinal":[180],"database.":[181],"nationwide":[184],"database,":[185],"containing":[186],"patient-level":[187],"structured":[188],"unstructured":[190],"data":[191],"curated":[192],"natural":[194],"language":[195],"processing":[196],"machine":[198],"learning":[199],"technology-enabled":[201],"abstraction,":[202],"includes":[203],">720,000":[204],"cancer.":[208],"Patients":[209,239,355],"diagnosed":[212],"(January":[216,260],"2017":[217],"July":[219],"2024),":[220],"or":[227,254],"4L":[228],"enrolled":[235],"trials.":[238],"assessed":[241],"from":[242,360],"start":[244],"(index":[247],"date)":[248],"death,":[250],"last":[251],"medical":[252],"activity,":[253],"end":[255],"available":[257],"follow-up":[259],"2025),":[261],"whichever":[262],"came":[263],"first.":[264],"Primary":[265],"included,":[267],"but":[268],"limited":[271],"to,":[272],"TTNT":[273,283,331,386],"OS":[275,285,340,388],"all":[277],"patients.":[278],"Exploratory":[279,346],"analyses":[280],"will":[281,348],"assess":[282],"stratified":[288],"by":[289],"BM":[290],"status,":[291],"duration":[292],"hormone":[297],"status.":[299],"Descriptive":[300],"statistics":[301],"used":[303],"patient":[305],"characteristics,":[306],"evaluated":[310],"Kaplan-Meier":[312],"analyses.":[313,353],"Results:":[314],"In":[315],"total,":[316],"92":[317],"received":[322],"Overall,":[327],"(95%":[329,338],"CI)":[330,339],"was":[332,341],"8.6":[333],"(5.7-11.6)":[334],"19.5":[342],"(12.0-26.1)":[343],"(Table).":[345],"presented":[350],"future":[352],"Conclusion:":[354],"benefit":[359],"demonstrating":[367],"its":[368],"clinically":[369],"meaningful":[370],"activity":[371],"contemporaneous":[374],"post-T-DXd":[375],"setting.":[376],"These":[377],"results":[378],"reinforce":[379],"effectiveness":[381],"tucatinib,":[383,428],"longer":[385],"than":[389],"previous":[391],"studies,":[393],"population":[396],"more":[397],"applicable":[398],"Citation":[403],"Format:":[404],"J.":[405],"Chien,":[406],"E.":[407],"Neuberger,":[408],"S.":[409,417],"Simon,":[410],"K.":[411],"Watkins,":[412],"G.":[413],"Curigliano,":[414],"B.":[415],"Li,":[416],"Stergiopoulos,":[418],"M.":[419],"Czachorowski,":[420],"H.":[421],"Itakura.":[422],"Us":[423],"trastuzumab,":[429],"her2+":[439],"[abstract].":[443],"In:":[444],"Proceedings":[445],"San":[448,457],"Antonio":[449],"Breast":[450],"Cancer":[451,464],"Symposium":[452],"2025;":[453],"2025":[454],"Dec":[455],"9-12;":[456],"Antonio,":[458],"TX.":[459],"Philadelphia":[460],"(PA):":[461],"AACR;":[462],"Clin":[463],"Res":[465],"2026;32(4":[466],"Suppl):Abstract":[467],"nr":[468],"PS5-01-28.":[469]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2026-02-18T00:00:00"}